Clinical Scorecard: Early Changes in Circulating Tumor DNA May Forecast Fruquintinib Response in Advanced Metastatic Colorectal Cancer Prior to Imaging Assessments
At a Glance
Category
Detail
Condition
Key Mechanisms
Circulating tumor DNA dynamics predict efficacy and prognosis during fruquintinib treatment, as per study findings.
Target Population
Care Setting
Key Highlights
Remove unsupported conclusion about modest discriminative performance.
Guideline-Based Recommendations
Diagnosis
Utilize circulating tumor DNA testing to assess treatment response, as indicated by study findings.
Management
Consider fruquintinib treatment for patients with refractory metastatic colorectal cancer, based on study results.
Monitoring & Follow-up
Monitor circulating tumor DNA dynamics at baseline, day 14, and day 28, as per study protocol.
Risks
Monitor for adverse events such as hypertension, hand-foot skin reaction, and fatigue, as reported in the study.
